Experts discuss a dynamic and multifaceted debate on frontline and subsequent treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), addressing the promise and challenges of combination therapies, central nervous system efficacy, long-term tolerability, sequencing complexities, and patient-centered decision-making in complex clinical scenarios to optimize outcomes amid evolving evidence and real-world considerations.
EP. 1: MARIPOSA: Final Overall Survival and Safety Insights From PALOMA-3, and COCOON
September 24th 2025Experts partake in a dynamic, debate-style educational event where teams present and challenge current frontline treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), focusing on the promise and practical challenges of combination therapy involving a bispecific antibody and third-generation EGFR tyrosine kinase inhibitor (TKI).
EP. 2: FLAURA2: Efficacy, Safety, CNS Outcomes, and Anticipated Overall Survival Results
September 24th 2025Experts have a compelling debate on first-line treatment for EGFR-mutated non–small cell lung cancer (NSCLC), weighing the robust survival and central nervous system (CNS) benefits of osimertinib plus chemotherapy against the promise of novel targeted strategies that aim to prevent resistance and push the boundaries of precision oncology.
EP. 3: Frontline Treatment Strategies for EGFRm NSCLC With Baseline Brain Metastases
October 2nd 2025Experts have a nuanced debate on frontline treatment for EGFR-mutant non–small cell lung cancer (NSCLC) with brain metastases, contrasting the central nervous system (CNS) efficacy and clinical familiarity of chemotherapy-based combinations with the precision and potential durability of newer targeted regimens, ultimately emphasizing individualized care and critical appraisal of trial data.
EP. 4: Striking an Optimal Balance Between Long-Term Efficacy and Tolerability
October 2nd 2025Experts discuss the trade-offs between long-term efficacy and real-world tolerability in EGFR-mutant non–small cell lung cancer (NSCLC) treatment, debating innovative targeted regimens vs familiar chemotherapy-based approaches and emphasizing the importance of personalized care, supportive infrastructure, and shared decision-making in optimizing outcomes.